Business
Celularity is a cellular and regenerative-medicine company built around placenta-derived therapies, biomaterial products, biobanking, and contract development services.
Celularity's revenue fell by half, losses widened, equity turned negative, and insiders stayed quiet.
The read at a glance✓ Audited against SEC data
- Business mix — Placenta-derived cell therapyNote
- Revenue — $26.6M, -51.0%Watch
- Net loss — ($91.7M), widerWatch
- Equity — ($38.1M), deficitWatch
- Debt — $33.8MWatch
- Insiders — 0 purchases and 0 salesNote
- Accounting — Altman weak; Beneish N/A; EQ greyWatch
Where the revenue comes from
Fiscal 2025, as Celularity Inc reports it. History and quarterly detail are in the app.
- Degenerative Disease$17.3M
- Biobanking$5.4M
- Cell Therapy$3.8M
Leadership changes
From Celularity Inc's own filings, the day they're filed.
- Vincent LeVien · Directors · departureeff. 2026-06-26
- Steven N. Gordon · Directors · appointmenteff. 2026-06-19
- K. Harold Fletcher · appointmenteff. 2026-06-19
Latest filings
- 8-K · Company announcement2026-08-07
- 8-K · Company announcement2026-07-29
- 8-K · Company announcement2026-06-30
- 8-K · Company announcement2026-06-25
- 8-K · Company announcement2026-06-12
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Celularity Inc, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.